nach oben

Irish Journal of Medical Science (1971 -)

Erschienen in:

27.05.2017 | Original Article

Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats

verfasst von: T. M. Ali, B. El Esawy, A. Elaskary

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study is designed to explore the effect of paricalcitol (vitamin D receptor agonist) on pancreatic oxidative stress, inflammatory markers, and adiponectin and glycemic status in diabetic rats.

Materials and methods

Forty Sprague-Dawley male rats aged 10–12 weeks (150–250 g) were used in this study. Type 2 diabetes was developed by providing 4 weeks of high-fat-diet feeding before one shot of streptozotocin injection (40 mg/kg i.p.). Four study groups were designed as normal control rats, diabetic control vehicle-treated, diabetic paricalcitol-treated (0.8 μg/kg), and diabetic glibenclamide-treated (0.6 mg/kg) groups with 10 animals in each. After treatment of diabetic rats for 3 months, pancreatic inflammatory and oxidative stress markers, plasma adiponectin, glycemic status parameters, and histopathological pancreatic islet changes were evaluated.

Results

Paricalcitol and glibenclamide treatment significantly (P < 0.05) decreased plasma glucose, insulin resistance, and pancreatic malondialdehyde and tumor necrosis factor-α levels. Moreover, they significantly (P < 0.05) increased plasma fasting insulin, C-peptide, adiponectin, pancreatic IL-2, catalase, superoxide dismutase, glutathione peroxidase, and reduced glutathione when contrasted with diabetic control rats. Furthermore, they prevented extensive histopathological damage in the pancreas of diabetic rats.

Conclusions

Paricalcitol reduced pancreatic oxidative stress and inflammatory markers, and improved glycemic status in diabetic rats.

American Diabetes Association (2009) Diagnosis and classification of diabetes mellitus. Diabetes Care 32(Suppl 1):S62–S67. doi:10.2337/dc09-S062 CrossRefPubMedCentral

Baynes JW, Thorpe SR (1999) The role of oxidative stress in diabetic complications. Curr Opin Endocrinol 3:277–284CrossRef

Yamamoto M, Yamato E, Toyoda S, Tashiro F, Ikegami H, Yodoi J et al (2008) Transgenic expression of antioxidant protein thioredoxin in pancreatic β cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal 10(1):43–49. doi:10.1089/ars.2007.1586 CrossRefPubMed

Alberici LC, Vercesi AE, Oliveira HCF (2011) Mitochondrial energy metabolism and redox responses to hypertriglyceridemia. J Bioenerg Biomembr 43(1):19–23CrossRefPubMed

Rösen P, Nawroth PP, King G, Möller W, Tritschler H-J, Packer L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society. Diabetes Metab Res Rev 17(3):189–212CrossRefPubMed

Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress—activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52(1):1–8CrossRefPubMed

Nishiyama A, Matsui M, Iwata S, Hirota K, Masutani H, Nakamura H et al (1999) Identification of thioredoxin-binding protein-2/vitamin D (3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem 274:21645–21650. doi:10.1074/jbc.274.31.21645 CrossRefPubMed

Lillig CH, Holmgren A (2007) Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal 9:25–47. doi:10.1089/ars. 2007.9.25 CrossRefPubMed

Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 11(2):136–140. doi:10.1038/ni.1831 CrossRefPubMed

10.

Simmons RA (2006) Developmental origins of diabetes: the role of oxidative stress. Free Radic Biol Med 40:917–922CrossRefPubMed

11.

Xuan Y, Zhao H-y, Liu J-M (2013) Vitamin D and type 2 diabetes mellitus (维生素D与2型糖尿病). J Diabetes 5:261–267. doi:10.1111/1753-0407.12024 CrossRefPubMed

12.

Navarro-González JF, Donate-Correa J, Méndez ML, de Fuentes MM, García-Pérez J, Mora-Fernández C (2013) Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. J Clin Pharmacol 53:421–426CrossRefPubMed

13.

Zitman-Gal T, Golan E, Green J, Bernheim J, Benchetrit S (2012) Vitamin D receptor activation in a diabetic-like environment: potential role in the activity of the endothelial pro-inflammatory and thioredoxin pathways. J Steroid Biochem Mol Biol 132(1–2):1–7CrossRefPubMed

14.

Ali TM, Esawy BHE, Elmorsy EA (2015) Effect of combining an angiotensin-converting enzyme inhibitor and a vitamin D receptor activator on renal oxidative and nitrosative stress in diabetic rats. Natl J Physiol Pharm Pharmacol 5(3):222–231CrossRef

15.

Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E (2009) Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 29(5):465–472CrossRefPubMed

16.

Suarez-Martinez E, Husain K, Ferder L (2014) Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice. Ther Adv Cardiovasc Dis 8(6):224–236. doi:10.1177/1753944714542593 CrossRefPubMedPubMedCentral

17.

Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11:85–97CrossRefPubMedPubMedCentral

18.

Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792CrossRefPubMedPubMedCentral

19.

Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14:561–566CrossRefPubMed

20.

Chattopadhyay E, Roy B (2017) Altered mitochondrial signalling and metabolism in cancer. Front Oncol 7:43. doi:10.3389/fonc.2017.00043 CrossRefPubMedPubMedCentral

21.

Song L, Pei L, Yao S, Wu Y, Shang Y (2017) NLRP3 inflammasome in neurological diseases, from functions to therapies. Front Cell Neurosci 11:63PubMedPubMedCentral

22.

Kewcharoenwong C, Rinchai D, Nithichanon A, Bancroft GJ, Ato M, Lertmemongkolchai G (2016) Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione. Sci Rep 6:34794CrossRefPubMedPubMedCentral

23.

Chugh SN, Dhawan R, Kishore K, Sharma A, Chugh K (2001) Glibenclamide vs gliclazide in reducing oxidative stress in patients of non-insulin dependent diabetes mellitus. A double blind randomized study. J Assoc Physicians India 49:803–807PubMed

24.

Ohta T, Katsuda Y, Miyajima K et al (2014) Gender differences in metabolic disorders and related diseases in spontaneously diabetic Torii-Leprfa rats. J Diabetes Res 2014:841957, 7 pages. doi:10.1155/2014/841957 CrossRefPubMedPubMedCentral

25.

Goodman J, Chandna A, Roe K (2015) Trends in animal use at US research facilities. J Med Ethics 41:567–569CrossRefPubMed

26.

Skovso S (2014) Modelling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Investig 5(4):349–357CrossRefPubMedPubMedCentral

27.

Mohsenifar Z, Feridoni MJ, Bayat M, Masteri Farahani R, Bayat S, Khoshvaghti A (2014) Histological and biomechanical analysis of the effects of streptozotocin-induced type one diabetes mellitus on healing of tenotomised Achilles tendons in rats. Foot Ankle Surg 20(3):186–191CrossRefPubMed

28.

Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ et al (2012) Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Am J Physiol Renal Physiol 302(1):F141–F149CrossRefPubMed

29.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed

30.

Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Ann Biochem 95:351–358CrossRef

31.

Proks P, Reimann F, Green N, Gribble F, Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51(suppl 3):S368–S376CrossRefPubMed

32.

Pittas AG, Lau J, Hu F, Dawson-Hughes B (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92(6):2017–2029. doi:10.1210/jc.2007-0298 CrossRefPubMedPubMedCentral

33.

Jayanarayanan S, Anju TR, Smijin S, Paulose CS (2015) Vitamin D3 supplementation increases insulin level by regulating altered IP3 and AMPA receptor expression in the pancreatic islets of streptozotocin-induced diabetic rat. J Nutr Biochem 26(10):1041–1049CrossRefPubMed

34.

Gagnon C, Daly RM, Carpentier A, Lu ZX, Shore-Lorenti C, Sikaris K (2014) Effects of combined calcium and vitamin D supplementation on insulin secretion, insulin sensitivity and β-cell function in multi-ethnic vitamin D-deficient adults at risk for type 2 diabetes: a pilot randomized, placebo-controlled trial. PLoS One 9(10):e109607. doi:10.1371/journal.pone.0109607 eCollection 2014CrossRefPubMedPubMedCentral

35.

Yang Z, Liu F, Qu H, Wang H, Xiao X, Deng H (2015) 1, 25(OH)2D3 protects β cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol 414:111–119CrossRefPubMed

36.

Boucher BJ (2011) Vitamin D insufficiency and diabetes risks. Curr Drug Targets 12:61–87CrossRefPubMed

37.

Yousefi Rad E, DJALALI M, KOOHDANI F et al (2014) The effects of vitamin D supplementation on glucose control and insulin resistance in patients with diabetes type 2: a randomized clinical trial study. Iran J Public Health 43(12):1651–1656PubMedPubMedCentral

38.

Jamka M, Woźniewicz M, Jeszka J, Mardas M, Bogdański P, Stelmach-Mardas M (2015) The effect of vitamin D supplementation on insulin and glucose metabolism in overweight and obese individuals: systematic review with meta-analysis. Sci Rep 5:16142. doi:10.1038/srep16142 CrossRefPubMedPubMedCentral

39.

Giugliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19:257–267CrossRefPubMed

40.

Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes 52:1–8CrossRefPubMed

41.

Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J (2000) Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 26:163–176PubMed

42.

Telci A, Cakatay U, Salman S, Satman I, Sivas A (2000) Oxidative protein damage in early stage in type 1 diabetic patients. Diabetes Res Clin Pract 50:213–223CrossRefPubMed

43.

Turk HM, Sevinc A, Camci C, Cigli A, Buyukberber S, Savli H, Bayraktar N (2002) Plasma lipid peroxidation products and antioxidant enzyme activities in patients with type 2 diabetes mellitus. Acta Diabetol 39:117–122CrossRefPubMed

44.

Subash-Babu P, Alshatwi AA, Ignacimuthu S (2014) Beneficial antioxidative and antiperoxidative effect of cinnamaldehyde protect streptozotocin-induced pancreatic β-cells damage in wistar rats. Biomol Ther 22(1):47–54. doi:10.4062/biomolther.2013.100 CrossRef

45.

Rahal A, Kumar A, Singh V et al (2014) Oxidative stress, prooxidants, and antioxidants: the interplay. Biomed Res Int 2014:761264. doi:10.1155/2014/761264 CrossRefPubMedPubMedCentral

46.

Izquierdo MJ, Cavia M, Muñiz P et al (2012) Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol 13:159. doi:10.1186/1471-2369-13-159 CrossRefPubMedPubMedCentral

47.

Sharma P, Jha AB, Dubey RS, Pessarakli M (2012) Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions. J Bot 2012:217037, 26 pages. doi:10.1155/2012/217037

48.

Husain K, Suarez E, Isidro A, Hernandez W, Ferder L (2015) Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis. World J Biol Chem 6(3):240–248. doi:10.4331/wjbc.v6.i3.240 CrossRefPubMedPubMedCentral

49.

Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE (2014) Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases. Physiol Rev 94(2):329–354. doi:10.1152/physrev.00040.2012 CrossRefPubMedPubMedCentral

50.

Longo AF, Vine DJ, King LE, Oakes M, Weber RJ, Huey LG, Russell AG, Ingall ED (2016) Composition and oxidation state of sulfur in atmospheric particulate matter. Atmos Chem Phys 16:13389–13398. doi:10.5194/acp-16-13389-2016 CrossRef

51.

Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J (2012) The role of oxidative stress and antioxidants in diabetic complications. Sultan Qaboos Univ Med J 12(1):5–18CrossRefPubMedPubMedCentral

52.

Husain K, Suarez E, Isidro A, Ferder L (2010) Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32(4):296–304CrossRefPubMed

53.

Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor–mediated sequestration of NF-κB signaling. Clin J Am Soc Nephrol: JASN 19(9):1741–1752. doi:10.1681/ASN.2007060666 CrossRef

54.

Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC (2007) 1,25-Dihydroxyvitamin D(3) targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 72:193–201CrossRefPubMed

55.

Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC (2006) Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab 291:E315–E322CrossRefPubMed

56.

Giarratana N, Penna G, Amuchastegui S, Mariani R, Daniel KC, Adorini L (2004) A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 173:2280–2287CrossRefPubMed

57.

Hwang HS, Yang KJ, Park KC et al (2013) Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxygenase-2 and prostaglandin E2. Nephrol Dial Transplant 28:1156–1166CrossRefPubMed

58.

Abdallah DM, Nassar NN, Abd-El-Salam RM (2011) Glibenclamide ameliorates ischemia-reperfusion injury via modulating oxidative stress and inflammatory mediators in the rat hippocampus. Brain Res 22(1385):257–262CrossRef

59.

Shimizu S, Oikawa R, Tsounapi P et al (2014) Blocking of the ATP sensitive potassium channel ameliorates the ischaemia-reperfusion injury in the rat testis. Andrology 2(3):458–465CrossRefPubMed

60.

Tsunekawa T, Hayashi T, Suzuki Y et al (2003) Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects. Diabetes Care 26(2):285–289CrossRefPubMed

61.

Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L (2001) Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Investig 108(12):1875–1881CrossRefPubMedPubMedCentral

62.

Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH et al (2009) Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 41(1):20–24PubMed

63.

Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148(3):293–300CrossRefPubMed

64.

Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941–946CrossRefPubMed

65.

DeClercq V, Stringer D, Hunt R, Taylor CG, Zahradka P (2011) Adipokine production by adipose tissue: a novel target for treating metabolic syndrome and its sequelae. In: Wang M (ed) Metabolic syndrome: underlying mechanisms and drug therapies. JohnWiley & Sons, Inc., Hoboken, pp 73–131CrossRef

Titel: Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats
verfasst von: T. M. Ali
B. El Esawy
A. Elaskary
Publikationsdatum: 27.05.2017
Verlag: Springer London
Erschienen in: Irish Journal of Medical Science (1971 -) / Ausgabe 1/2018
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-017-1635-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effect of paricalcitol on pancreatic oxidative stress, inflammatory markers, and glycemic status in diabetic rats

Abstract

Objectives

Materials and methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Trends in corneal transplant surgery in Ireland: indications and outcomes of corneal transplant surgery and intraocular lens opacification following Descemet’s stripping automated endothelial keratoplasty

Peer teaching as a means of enhancing communications skills in anaesthesia training: trainee perspectives

In recognition of Ireland’s clinical medical researchers: Noel G McElvaney, T Joseph McKenna, Noel Caplice and Bryan Hennessy

Prospective evaluation of a virtual urology outpatient clinic

Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent’s University Hospital over a 6-month period

Advanced practice physiotherapy in paediatric orthopaedics: innovation and collaboration to improve service delivery

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin